Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study
Language English Country Ireland Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
34482090
DOI
10.1016/j.atherosclerosis.2021.08.035
PII: S0021-9150(21)01308-3
Knihovny.cz E-resources
- Keywords
- Atherosclerosis, Cardiovascular, Dyslipidaemia, Low-density lipoprotein cholesterol,
- MeSH
- Dyslipidemias * diagnosis drug therapy epidemiology MeSH
- Cardiovascular Diseases * diagnosis drug therapy prevention & control MeSH
- Humans MeSH
- Lipids MeSH
- Cross-Sectional Studies MeSH
- Risk Factors MeSH
- Secondary Care MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
- Poland MeSH
- Names of Substances
- Lipids MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * MeSH
BACKGROUND AND AIMS: Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. METHODS: The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. RESULTS: In total, 2154 patients were enrolled from the Czech Republic (n = 509), Hungary (n = 319), Poland (n = 460), Romania (n = 259), Slovakia (n = 123) and Ukraine (n = 484). At LDL-C measurement, most patients were on either moderate- or high-intensity statin monotherapy (53% and 32%, respectively). Despite this, only 44% of patients achieved risk-based LDL-C goals recommended by the 2016 ESC/EAS guidelines, ranging from 21% in Ukraine to 50% in Hungary and Romania. Only 24% of patients overall achieved the risk-based LDL-C goals recommended by the 2019 ESC/EAS guidelines, ranging from 11% in Ukraine to 32% in Poland. CONCLUSIONS: Among patients receiving lipid-lowering therapy, more than half did not achieve their 2016 LDL-C goals. In one of the first comparative analyses evaluating 2019 risk-based goal attainment among countries in CEE, three-quarters of patients did not meet their 2019 LDL-C goals, highlighting a significant gap between guidelines and clinical practice for lipid management in CEE.
Amgen Sro 110 02 Prague 1 Czech Republic
Coordination Center for Familial Hyperlipidemia Slovak Medical University 833 03 Bratislava Slovakia
Global Biostatistical Science Amgen Ltd 240 Cambridge Science Park Milton Road Cambridge CB4 0WD UK
Hungarian Army Medical Center Budapest 1134 Hungary
Institute of General Practice Charles University 128 00 Prague 2 Czech Republic
References provided by Crossref.org
